M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Contrast Agent
Procedure: Contrast-Enhanced Mammography
Other: Questionnaire Administration

First Posted Date: 2021-09-16

Last Posted Date: 2024-06-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 151

Registration Number: NCT05046301

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

Not Applicable

Recruiting

Conditions: Tobacco Use Disorder
Depression

Interventions: Procedure: Discussion
Behavioral: Behavioral Activation Therapy
Behavioral: Health Education
Other: Questionnaire Administration
Other: Tobacco Cessation Counseling

First Posted Date: 2021-09-14

Last Posted Date: 2023-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 99

Registration Number: NCT05044546

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis

Not Applicable

Not yet recruiting

Conditions: GI Cancers
Gastrointestinal Cancer

Interventions: Other: Sleeping Disturbances

First Posted Date: 2021-09-14

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05044312

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement

Phase 2

Recruiting

Conditions: Malignant Pleural Neoplasm

Interventions: Drug: Lidocaine
Drug: Liposomal Bupivacaine
Other: Questionnaire Administration

First Posted Date: 2021-09-14

Last Posted Date: 2024-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT05044468

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Phase 1

Withdrawn

Conditions: Metastatic Ewing Sarcoma
Recurrent Ewing Sarcoma

Interventions: Procedure: Fine-Needle Aspiration
Drug: Irinotecan
Drug: Irinotecan Hydrochloride
Drug: Lurbinectedin

First Posted Date: 2021-09-13

Last Posted Date: 2022-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05042934

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial

Phase 3

Completed

Conditions: Fatigue
Cancer

Interventions: Drug: Methylphenidate
Other: Placebo (Sugar Pill)

First Posted Date: 2021-09-13

Last Posted Date: 2022-09-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 112

Registration Number: NCT05041946

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Tc99m sestamibi

First Posted Date: 2021-09-13

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT05042687

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome

Not Applicable

Withdrawn

Conditions: Breast Carcinoma

Interventions: Procedure: Massage Therapy
Procedure: Acupuncture Point Injection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-09-13

Last Posted Date: 2022-05-17

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05041751

Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)

Not Applicable

Recruiting

Conditions: Prostate Cancer

Interventions: Device: flexible AIR coil
Device: endorectal coi

First Posted Date: 2021-09-13

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 258

Registration Number: NCT05043012

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Phase 2

Recruiting

Conditions: Chordoma
Metastatic Chordoma
Unresectable Chordoma

Interventions: Biological: Cetuximab
Other: Questionnaire Administration

First Posted Date: 2021-09-10

Last Posted Date: 2024-08-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05041127

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy